Cantor Fitzgerald raised its price target on Valeant Pharmaceuticals (NYSE: VRX) to $23.00 (from $18.00) while maintaining a Overweight rating.Analyst ...(Premium-only article. Please sign in or upgrade to SI Premium to view.)